Simple blood tests may help predict ovarian cancer treatment success
NCT ID NCT07678008
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study investigates whether certain blood-based markers, such as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and the CA-125 elimination rate (KELIM score), can predict survival and surgical outcomes in women with advanced ovarian cancer. Researchers will review medical records of 80 patients who received chemotherapy before surgery. The goal is to see if these markers can help forecast how long patients live without the disease worsening and whether surgery will be successful.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors better predict which patients with advanced ovarian cancer will respond to chemotherapy and surgery, potentially guiding more personalized treatment plans.
What could go wrong
This is a small, retrospective study, so results may not apply to all patients. The markers studied are not yet proven to be reliable enough for routine clinical use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE SEROUS OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sohag university hospital
Sohag, Egypt